KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.70
+7.46 (38.77%)
Apr 29, 2026, 9:30 AM EDT - Market open
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock have an average target of 32.6, with a low estimate of 20 and a high estimate of 42. The average target predicts an increase of 22.10% from the current stock price of 26.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2026.
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 3 | 4 | 3 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 5 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $39 → $42 | Strong Buy | Maintains | $39 → $42 | +57.30% | Mar 26, 2026 |
| Citizens | Citizens | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +4.87% | Mar 26, 2026 |
| Needham | Needham | Strong Buy Maintains $35 → $36 | Strong Buy | Maintains | $35 → $36 | +34.83% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $37 | Strong Buy | Maintains | $27 → $37 | +38.58% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $32 → $35 | Strong Buy | Maintains | $32 → $35 | +31.09% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
210.12M
from 73.62M
Increased by 185.42%
Revenue Next Year
334.58M
from 210.12M
Increased by 59.23%
EPS This Year
-1.09
from -3.05
EPS Next Year
0.87
from -1.09
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 261.8M | 458.0M | ||||||
| Avg | 210.1M | 334.6M | ||||||
| Low | 178.7M | 228.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 255.6% | 118.0% | ||||||
| Avg | 185.4% | 59.2% | ||||||
| Low | 142.7% | 8.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.38 | 3.78 | ||||||
| Avg | -1.09 | 0.87 | ||||||
| Low | -1.28 | -0.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.